Clinical Pathways as Instruments for Risk and Cost Management in Hospitals - A Discussion Paper

Abstract

Introduction:The distinctive characteristics of the German health system are medical progress and financial pressure—and this is especially true of the hospitals. These challenges must be met by strategic management instruments for quality assurance, and by reducing costs.Purpose:This article presents the instrument “clinical pathway” (also known as “clinical treatment pathway”) and describes the possibilities it offers, both for quality assurance and risk management, and for cost reduction. The clinical pathway presented here will be that for “multimodal pain therapy”, as used in the context of acute inpatient care in Germany.Methods:A general presentation of the risks in hospital is followed by consideration of the risks associated with core processes. A comprehensive total cost analysis is performed for those patients who meet the pathway entry criteria and who fulfil the requirements for the structure of care provided within multimodal pain therapy.Discussion and Conclusion:Multimodal pain therapy places high demands on the structural, procedural and outcome quality of the medical, nursing and therapeutic services provided, and these demands are reflected in high costs for the provision of this care. The treatment process involves many different professional groups. These complex interfaces can potentially generate risks, which can lead to the possibility of legal liability. A clinical pathway must structure the core process and then combine elements of quality assurance in order to optimise patient care and minimise risk. The examination of costs reveals significant potential savings (patients with clinical pathway: EUR 3086±212; patients without clinical pathway: EUR 3774±460; Mann-Whitney U test; p<0.001). For the managers of a hospital, the clinical pathway represents a strategic management instrument that can serve for continual cost control and cost reduction, and can contribute in the form of quality assurance towards a transparent provision of services.

Multi-Modal Pain Therapy of Fibromyalgia Syndrome with Integration of Systemic Whole-Body Hyperthermia – Effects on Pain Intensity and Mental State: A Non-Randomised Controlled Study

“…Study participants always retained the right to withdraw at any time for any reason. Figure 1 shows the structure of the treatment pathway followed by a total of 130 patients (42). Twenty six patients were excluded from the study investigation because they deviated significantly from the treatment pathway.…”

Ensuring Quality in Interdisciplinary Inpatient Chronic Care

“…Professional medical associations should, therefore, continue to interpret the codes. This is also vital to avoid patient-related adverse effects of P4Q (Chang et al, 2012) due to ambiguity regarding remuneration (Romeyke & Stummer, 2012). The potential payer-related adverse effect is falsifying patient documentation (Allen et al, 2014) to obtain financial benefits.…”

Severe forms of fibromyalgia with acute exacerbation of pain: costs, comorbidities, and length of stay in inpatient care

“…As part of a cost-of-illness study, economic data analysis and its results provide important information for health-policy makers, hospital managers, and the general public 44. Moreover, it can be used as starting point for benchmarking projects and create a basis for process optimization 45. The results of the assessments clearly show, however, that severe forms of FMS are typically associated with a high number of failed treatments.…”